Benzocaína e eugenol como anestésicos para o quinguio (Carassius auratus) / Benzocaine and eugenol as anesthetics for golden fish (Carassius auratus)

Avaliaram-se os tempos de indução e recuperação de quinguios (Carassius auratus) expostos a dois anestésicos, eugenol e benzocaína. Foram utilizados 128 juvenis com peso médio de 2,07±0,53g e comprimento total médio de 5,51±0,56cm. A benzocaína mostrou ser mais eficiente do que o eugenol em relação ao tempo, tanto para indução ao coma quanto para a recuperação à fuga e também no que diz respeito à sobrevivência. As doses de benzocaína com melhores resultados foram de 87,5 e 100mg.L-1. O eugenol proporcionou demora na indução e na recuperação dos animais, além de ter apresentado mortalidades quando as doses anestésicas foram elevadas.

The aim of this work was to evaluate the induction and recuperation time of quinguio (Carassius auratus) exposed to two anesthetics, eugenol and benzocaine. 128 juveniles with 2.07±0.53g of average weight and 5.51±0.56cm of total length were used. The benzocaine proved to be more efficient than the eugenol regarding the time in inducing a coma and recovering flight, as well as survival. The better results of benzocaine doses were 87.5 and 100mg.L-1. The eugenol resulted in a delay of animal induction and recovery, and also presented mortalities when the anesthetics doses were increased.

Glial cell activity is maintained during prolonged inflammatory challenge in rats

We evaluated the expression of glial fibrillary acidic protein (GFAP), glutamine synthetase (GS), ionized calcium binding adaptor protein-1 (Iba-1), and ferritin in rats after single or repeated lipopolysaccharide (LPS) treatment, which is known to induce endotoxin tolerance and glial activation. Male Wistar rats (200-250 g) received ip injections of LPS (100 µg/kg) or saline for 6 days: 6 saline (N = 5), 5 saline + 1 LPS (N = 6) and 6 LPS (N = 6). After the sixth injection, the rats were perfused and the brains were collected for immunohistochemistry. After a single LPS dose, the number of GFAP-positive cells increased in the hypothalamic arcuate nucleus (ARC; 1 LPS: 35.6 ± 1.4 vs control: 23.1 ± 2.5) and hippocampus (1 LPS: 165.0 ± 3.0 vs control: 137.5 ± 2.5), and interestingly, 6 LPS injections further increased GFAP expression in these regions (ARC = 52.5 ± 4.3; hippocampus = 182.2 ± 4.1). We found a higher GS expression only in the hippocampus of the 6 LPS injections group (56.6 ± 0.8 vs 46.7 ± 1.9). Ferritin-positive cells increased similarly in the hippocampus of rats treated with a single (49.2 ± 1.7 vs 28.1 ± 1.9) or repeated (47.6 ± 1.1 vs 28.1 ± 1.9) LPS dose. Single LPS enhanced Iba-1 in the paraventricular nucleus (PVN: 92.8 ± 4.1 vs 65.2 ± 2.2) and hippocampus (99.4 ± 4.4 vs 73.8 ± 2.1), but had no effect in the retrochiasmatic nucleus (RCA) and ARC. Interestingly, 6 LPS increased the Iba-1 expression in these hypothalamic and hippocampal regions (RCA: 57.8 ± 4.6 vs 36.6 ± 2.2; ARC: 62.4 ± 6.0 vs 37.0 ± 2.2; PVN: 100.7 ± 4.4 vs 65.2 ± 2.2; hippocampus: 123.0 ± 3.8 vs 73.8 ± 2.1). The results suggest that repeated LPS treatment stimulates the expression of glial activation markers, protecting neuronal activity during prolonged inflammatory challenges.